Developing therapies to target multiple immune pathways
17 Jun 2024
Salon D
Bi/Multispecifics
- Which formats have better clinical success – VHH vs Ig-like vs non-Ig-like molecules?
- Immunogeneicity concerns for non-Ig-like formats
- Manufacturing challenges especially for multi-specific antibodies
- How will Cryo-EM and AI/ML assist in designing future bispecific & multispecific antibodies?
- Future of IgM-like multi-specific antibodies: Would it overcome potential immunogeneicity concern? What about manufacturing challenges?
